David C. Stieg
YOU?
Author Swipe
View article: The Ashkenazi-Centric G334R Variant of <i>TP53</i> is Severely Impaired for Transactivation but Retains Tumor Suppressor Function in a Mouse Model
The Ashkenazi-Centric G334R Variant of <i>TP53</i> is Severely Impaired for Transactivation but Retains Tumor Suppressor Function in a Mouse Model Open
Mutations in the TP53 tumor suppressor gene are the most abundant genetic occurrences in cancer. Some of these mutations lead to loss of function of p53 protein, some are gain of function, and some variants are hypomorphic (partially funct…
View article: Cyclin C Promotes Pancreatic Development and Suppresses Cancer Initiation Through Maintenance of the Autophagy-Lysosome Pathway
Cyclin C Promotes Pancreatic Development and Suppresses Cancer Initiation Through Maintenance of the Autophagy-Lysosome Pathway Open
The cyclin C (Ccnc)-Cdk8/Cdk19 kinases are components of the Mediator that represses or activates gene transcription. The present study found that Ccnc is required for both steady state and induced autophagic gene transcription in mouse em…
View article: FIGURE 7 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 7 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
S47 mice are less responsive to PD-L1 blockade therapy. A, Tumor growth curves for P47 and S47 mice treated with rat IgG2b isotype control antibody or anti-PD-L1 antibody following MC38 cell injections. n = 7 P47 IgG2b isotype control; n =…
View article: Table S1 and S2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Table S1 and S2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Table S1 and Table S2
View article: FIGURE 2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Differences in memory T-cell formation and chemokine receptor usage in S47 mice. Splenocytes derived from non–tumor-bearing, male S47 and P47 mice between the ages of 6 and 10 weeks were analyzed by flow cytometry for differences in baseli…
View article: FIGURE 1 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 1 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
The tumor growth advantage in S47 mice is abolished following CD8+ T-cell depletion. A, Illustration of the experimental approach. Replicate P47 and S47 mice were injected subcutaneously with 1 × 106 MC38 tumor cells. At day 19, spleens an…
View article: FIGURE 2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Differences in memory T-cell formation and chemokine receptor usage in S47 mice. Splenocytes derived from non–tumor-bearing, male S47 and P47 mice between the ages of 6 and 10 weeks were analyzed by flow cytometry for differences in baseli…
View article: Figure S1 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Figure S1 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Figure S1 shows BMDMs from S47 mice are more anti-inflammatory and polarize towards a M2 phenotype following IL-4 stimulation.
View article: FIGURE 7 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 7 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
S47 mice are less responsive to PD-L1 blockade therapy. A, Tumor growth curves for P47 and S47 mice treated with rat IgG2b isotype control antibody or anti-PD-L1 antibody following MC38 cell injections. n = 7 P47 IgG2b isotype control; n =…
View article: FIGURE 6 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 6 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
TILs in S47 mice exhibit elevated coexpression of multiple IRs. Tumors and spleens were harvested 21 days after injection of MC38 cells and T cells were analyzed for surface expression of multiple IRs by flow cytometry. Comparison of frequ…
View article: FIGURE 6 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 6 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
TILs in S47 mice exhibit elevated coexpression of multiple IRs. Tumors and spleens were harvested 21 days after injection of MC38 cells and T cells were analyzed for surface expression of multiple IRs by flow cytometry. Comparison of frequ…
View article: FIGURE 3 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 3 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
S47-derived T cells display a steady-state deficit in effector T-cell function after stimulation. RBC-depleted splenocytes from either S47 or P47 mice were stimulated with PMA/Ionomycin, Concanavalin A, or anti-CD3/CD28 Dynabeads, then ass…
View article: Table S1 and S2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Table S1 and S2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Table S1 and Table S2
View article: FIGURE 5 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 5 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Tumor-infiltrating T cells in S47 mice display uniquely elevated transcription factor profiles. Tumors and spleens were harvested 21 days after injection of MC38 cells and T cells were analyzed for transcription factor expression by intran…
View article: FIGURE 4 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 4 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Tumor-bearing S47 mice harbor more immunosuppressive splenic immune cell profiles. A, Flow cytometry analyses on splenocytes from TBM for percent positive MDSCs in P47 and S47 mice, respectively. Bar graph on right shows the percent positi…
View article: FIGURE 1 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 1 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
The tumor growth advantage in S47 mice is abolished following CD8+ T-cell depletion. A, Illustration of the experimental approach. Replicate P47 and S47 mice were injected subcutaneously with 1 × 106 MC38 tumor cells. At day 19, spleens an…
View article: FIGURE 5 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 5 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Tumor-infiltrating T cells in S47 mice display uniquely elevated transcription factor profiles. Tumors and spleens were harvested 21 days after injection of MC38 cells and T cells were analyzed for transcription factor expression by intran…
View article: Figure S2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Figure S2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Figure S2 shows that the tumor microenvironment in both P47 and S47 mice is comprised of similar proportions of subpopulations of immune cells with similar phenotypes.
View article: FIGURE 4 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 4 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Tumor-bearing S47 mice harbor more immunosuppressive splenic immune cell profiles. A, Flow cytometry analyses on splenocytes from TBM for percent positive MDSCs in P47 and S47 mice, respectively. Bar graph on right shows the percent positi…
View article: FIGURE 3 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
FIGURE 3 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
S47-derived T cells display a steady-state deficit in effector T-cell function after stimulation. RBC-depleted splenocytes from either S47 or P47 mice were stimulated with PMA/Ionomycin, Concanavalin A, or anti-CD3/CD28 Dynabeads, then ass…
View article: Figure S1 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Figure S1 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Figure S1 shows BMDMs from S47 mice are more anti-inflammatory and polarize towards a M2 phenotype following IL-4 stimulation.
View article: Figure S2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Figure S2 from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Figure S2 shows that the tumor microenvironment in both P47 and S47 mice is comprised of similar proportions of subpopulations of immune cells with similar phenotypes.
View article: Table S1 and S2 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Table S1 and S2 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Table S1 and Table S2
View article: The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
The tumor suppressor TP53 is the most frequently mutated gene in cancer and is mutationally inactivated in 50% of sporadic tumors. Inactivating mutations in TP53 also occur in Li Fraumeni syndrome (LFS). In addition to germline mutations i…
View article: Data from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Data from The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
The tumor suppressor TP53 is the most frequently mutated gene in cancer and is mutationally inactivated in 50% of sporadic tumors. Inactivating mutations in TP53 also occur in Li Fraumeni syndrome (LFS). In addition to germline mutations i…
View article: Figure S2 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Figure S2 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Figure S2 shows that the tumor microenvironment in both P47 and S47 mice is comprised of similar proportions of subpopulations of immune cells with similar phenotypes.
View article: Data from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Data from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
The tumor suppressor TP53 is the most frequently mutated gene in cancer and is mutationally inactivated in fifty percent of sporadic tumors. Inactivating mutations in TP53 also occur in Li Fraumeni syndrome (LFS). In addition to germline m…
View article: Table S1 and S2 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Table S1 and S2 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Table S1 and Table S2
View article: Figure S1 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Figure S1 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Figure S1 shows BMDMs from S47 mice are more anti-inflammatory and polarize towards a M2 phenotype following IL-4 stimulation.
View article: Figure S1 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
Figure S1 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition Open
Figure S1 shows BMDMs from S47 mice are more anti-inflammatory and polarize towards a M2 phenotype following IL-4 stimulation.